Course Evaluations Step 1 of 4 - Friday, June 25 0% Friday, June 25The Advocacy Council Insider: Navigating the Regulatory Alphabet Soup - James L. Sublett, MD, FACAAI At the end of this presentation, participants should be able to: 1. Ensure their individual office staff and mixing areas are compliant with USP 797 requirements 2. Understand rationale for CPT codes recommended by the Advocacy Council for FDA approved OIT 3. Improve the management and billing of biologics in their practiceRate the overall importance of this session.Do you intend on making any changes in your practice as a result of this presentation? Yes No Combatting Dr. Google - David Stukus, MD Objectives: 1. Identify the sources of misinformation available to our patients 2. Discuss medical myths and misinformation with our patients 3. Explain the potentially beneficial role of Social Media in Medical practiceRate the overall importance of this session.Do you intend on making any changes in your practice as a result of this presentation? Yes No Town Hall Meeting: An Update on Advocacy and on Legislation Affecting Allergists - James L. Sublett, MD, FACAAI, Barbara Weissman, MD & Kevin Pedrotti Objectives (Dr. Sublett) At the end of this discussion you will be informed on the following issues: • CPT 95165 – advocate reasonable limits • Alternative Payment Models (APMs) - CMS/HHS’ failure to seriously consider/approve any alternative payment models. • Narrow Networks/Surprise Medical Bills - • Telehealth - Ensure telehealth remains a covered service throughout and after the PHE. • Step Therapy/Prior Authorization - restrict insurance carrier’s ability to impose unreasonable requirements. • Restructure of the College’s House of Delegates Objectives (Dr. Weissman) 1. Review CMA’s response to the COVID pandemic 2. Evaluate key legislative medical topics in our state 3. Summarize strategies to promote advocacy for patient care issuesRate the overall importance of this session.Do you intend on making any changes in your practice as a result of this presentation? Yes No Top Allergy Paper: Anaphylaxis after Administration of Novel mRNA COVID 19 Vaccines - Shalin Pandya, DO Objectives: 1. Upon completion of this leaning activity, participants should be able to recognize clinical presentation of anaphylaxis and methods to classify themRate the overall importance of this session.Do you intend on making any changes in your practice as a result of this presentation? Yes No Saturday, June 26Inborn Errors of Immunity (IEI) Overlaps with Autoimmunity - Manish J. Butte, MD, PhD Objectives: 1. Overview of IEIs 2. Understand nine immunological and genetic bases of monogenic autoimmune diseasesRate the overall importance of this session.Do you intend on making any changes in your practice as a result of this presentation? Yes No Genetics and Molecular Mechanisms of Antibody Deficiencies (“CVID”) - Manish J. Butte, MD, PhD Objectives: 1. Introduction to IEI and Genetic testing 1. Gene Panels 2. Whole exome sequencing and its limitations 3. Whole genome sequencing 4. RNA sequencing 2. Describe the underlying genetic defects and phenotypes of predominantly antibody deficiencies 3. Our research to identify subgroups of antibody deficiency patientsRate the overall importance of this session.Do you intend on making any changes in your practice as a result of this presentation? Yes No Emerging Therapies for Food Allergy and the Role and Implementation of OIT and OIT in a Clinical Practice - Anna H. Nowak-Wegrzyn, MD Objectives: 1. Compare routes of food immunotherapy regarding safety and efficacy 2. Describe the role and implementation of food oral immunotherapy in a clinical practice 3. Describe novel biologics for food allergyRate the overall importance of this session.Do you intend on making any changes in your practice as a result of this presentation? Yes No Prevention of Food Allergies - Anna H. Nowak-Wegrzyn, MD Objectives: 1. Describe current approaches to food allergy prevention 2. Compare evidence regarding early introduction of food allergens, skin care, and microbiota modificationRate the overall importance of this session.Do you intend on making any changes in your practice as a result of this presentation? Yes No Use of Biologics for Nasal Polyps: A Surgeon’s Perspective - Arthur Wu, MD Objectives: 1. Become familiar with state-of-the-art diagnosis and treatment of CRSwNP 2. Integrate treatment algorithm for CRSwNP 3. Identify deficits in current knowledge regarding biologics for CRSwNPRate the overall importance of this session.Do you intend on making any changes in your practice as a result of this presentation? Yes No Eustachian Tube Dysfunction Diagnosis and Treatment - Arthur Wu, MD Objectives: 1. Become adept at differentiating Eustachian tube dysfunction with common alternate diagnoses that mimic its symptoms 2. Become familiar with emerging technologies to treat Eustachian tube dysfunctionRate the overall importance of this session.Do you intend on making any changes in your practice as a result of this presentation? Yes No Sunday, June 27Systemic Therapies and Emerging Therapeutics for Atopic Dermatitis - Peter Lio, MD Objectives: 1. Describe the existing systemic therapies that are commonly used for treating atopic dermatitis 2. Outline the key pathophysiologic pathways being targeted for emerging treatments 3. Identify some of the key studies on emerging therapies for atopic dermatitisRate the overall importance of this session.Do you intend on making any changes in your practice as a result of this presentation? Yes No Advanced Therapeutics of Atopic Dermatitis - Peter Lio, MD Objectives: 1. Describe non-pharmacologic approaches to treating atopic dermatitis, including creating an eczema action plan 2. Outline some of the potential benefits of a multi-pronged therapeutic approach to atopic dermatitis 3. Identify some pitfalls, limitations, and knowledge gaps in atopic dermatitisRate the overall importance of this session.Do you intend on making any changes in your practice as a result of this presentation? Yes No Asthma 2021: From Mechanisms to Precision Medicine - Monica Kraft, MD Objectives: 1. Discuss significant changes to asthma guidelines 2. Discuss new areas of asthma pathobiology 3. Discuss use of a biomarker driven approach to deliver personalized or precision medical care to patients with severe asthmaRate the overall importance of this session.Do you intend on making any changes in your practice as a result of this presentation? Yes No Biologics and Therapeutics in Severe Asthma - Monica Kraft, MD Objectives: 1. Discuss the pipeline of biologics in asthma 2. Discuss a new direction of therapeutics in asthma 3. Discuss precision-based approaches in asthma researchRate the overall importance of this session.Do you intend on making any changes in your practice as a result of this presentation? Yes No What are your credentials?* MD / DO NP PA RN PharmD RPh PhD What is your specialty?* Activity contentBased upon information you received from this activity, please list at least two applications that can be made to your clinical practice.What degree of confidence do you have that you will apply your “new” learning in your practice?*The activity was free of commercial bias?* Yes No Please elaborate why you felt this activity as not free of commercial bias*Disclosure of potential conflicts of interest by faculty were clearly communicated?* Yes No Please elaborate why you felt there were conflicts of interest.*Activity contentDescribe two particularly strong features of this program:Describe two areas for improvement you would like to see:List three topics or experts you would find interesting and professionally relevant for future WSAAI meetings:General comments and suggestions:Name* First Last Suffix Address Street Address Address Line 2 City State / Province / Region ZIP / Postal Code AfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCabo VerdeCambodiaCameroonCanadaCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos IslandsColombiaComorosCongoCongo, Democratic Republic of theCook IslandsCosta RicaCroatiaCubaCuraçaoCyprusCzechiaCôte d'IvoireDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatiniEthiopiaFalkland IslandsFaroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard Island and McDonald IslandsHoly SeeHondurasHong KongHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKorea, Democratic People's Republic ofKorea, Republic ofKuwaitKyrgyzstanLao People's Democratic RepublicLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacaoMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorth MacedoniaNorthern Mariana IslandsNorwayOmanPakistanPalauPalestine, State ofPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto RicoQatarRomaniaRussian FederationRwandaRéunionSaint BarthélemySaint Helena, Ascension and Tristan da CunhaSaint Kitts and NevisSaint LuciaSaint MartinSaint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint MaartenSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan MayenSwedenSwitzerlandSyria Arab RepublicTaiwanTajikistanTanzania, the United Republic ofThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkmenistanTurks and Caicos IslandsTuvaluTürkiyeUS Minor Outlying IslandsUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVenezuelaViet NamVirgin Islands, BritishVirgin Islands, U.S.Wallis and FutunaWestern SaharaYemenZambiaZimbabweÅland Islands Country Email Enter Email Confirm Email
